Device / Technology News

RSS

Verax Biomedical receives FDA clearance for Platelet PGD test

A $30 test that takes fewer than 30 minutes to perform can prevent potentially deadly transfusions of bacterial contamination in platelets, according to a new study published in the peer-reviewed journal Transfusion. An early view of the study can be found at the journal's web site.

23 Sep 2011

Cambridge Heart enters agreement with EO Medical for MTWA technology

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced that it has executed an exclusive agreement with EO Medical Pte Ltd to distribute its HearTwave II System and proprietary Microvolt T-Wave Alternans (MTWA) software and Micro-V Alternans Sensors in Singapore upon regulatory approval.

22 Sep 2011

Gynesonics initiates VizAblate FAST-EU study for uterine fibroid treatment

Gynesonics, Inc., a women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids, today announced the start of, and initial treatments in, the FAST-EU Trial, a multicenter clinical study to demonstrate the effectiveness of the VizAblate® procedure for the treatment of uterine fibroids associated with heavy menstrual bleeding.

22 Sep 2011

Neogen develops quick and easy new test for aflatoxin

Neogen Corporation has developed a quick and easy new test for aflatoxin, a toxin considered by many to be the most potent, naturally-occurring carcinogen. The toxin is a by-product of mold growth in a wide range of commodities, including corn.

22 Sep 2011

New portable test can quickly and economically detect adulterated heparin

Scientists are reporting refinement of a new test that promises to help assure the safety of supplies of heparin, the blood thinner taken by millions of people worldwide each year to prevent blood clots.

22 Sep 2011

Quidel, Life Technologies to distribute and commercialize molecular diagnostics in Europe

Life Technologies Corporation today announced that the company has signed an agreement with Quidel Corporation to distribute and commercialize molecular diagnostic assays for the European market.

22 Sep 2011

OPTOS to acquire ophthalmic instrumentation business from OPKO

OPKO Health, Inc. has agreed to sell its ophthalmic instrumentation business to OPTOS, Inc., a subsidiary of Optos plc, a leading and rapidly growing medical technology company engaged in the design, development, manufacture and marketing of devices to image the retina of the eye. Optos will pay OPKO $17.5 million in cash at closing, plus future royalties.

22 Sep 2011

InSightec's ExAblate Neuro system may treat chronic brain disorders

InSightec Ltd., the global leader in MR guided Focused Ultrasound (MRgFUS) technology, announced today that its investigational ExAblate(R) Neuro system has been used in clinical studies to treat 30 patients suffering from chronic neurological disorders.

22 Sep 2011

NanoString's miRGE Assay now available for use in nCounter Analysis System

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of the nCounter miRGE Assay for use on its nCounter Analysis System.

From NanoString Technologies 22 Sep 2011

Sapheon's new varicose vein closure system receives European CE Mark approval

Sapheon Inc. announced that it has received CE Mark approval for its new approach to the treatment of varicose veins caused by venous reflux disease.

22 Sep 2011

Test to properly diagnose fever in children needed 'desperately'

"[F]ar too many children in Kenya and other African countries continue to suffer unnecessarily each year due to the misdiagnosis of fever, which contributes to the deaths of nearly three million children of less than five years of age from malaria and pneumonia," Willis Akhwale, head of Kenya's Department of Disease Prevention and Control in the Ministry of Public Health and Sanitation, writes in a Daily Nation opinion piece.

21 Sep 2011

Saladax, Bristol-Myers Squibb expand Alzheimer's diagnostic assays agreement

Bristol-Myers Squibb Company and Saladax Biomedical, Inc., announced today they have expanded their multi-year agreement covering the development and commercialization of diagnostic assays for the early detection of Alzheimer's disease to include Ortho-Clinical Diagnostics, Inc.

21 Sep 2011

Two IGB faculty members recognized as University Scholars

Paul Kenis and James Slauch have been named as University Scholars, a program created to recognize the university's most talented teachers, scholars and researchers.

21 Sep 2011

IRIDEX licenses rights to Ocunetics' intellectual property

IRIDEX Corporation today announced that it has exclusively licensed the rights to all of the intellectual property of Ocunetics, Inc., a privately held company based in Alamo, California. Ocunetics develops procedure-enabling medical devices that are intended to increase surgeons' efficiency, while improving case predictability for ophthalmic surgeries.

21 Sep 2011

Influential leaders hold high-level discussions on biomedical S&T initiatives

Influential leaders from the medical and research communities held high-level discussions on biomedical science and technology (S&T) initiatives at the Office of Naval Research (ONR), Sept. 16.

21 Sep 2011

GI Dynamics introduces EndoBarrier Gastrointestinal Liner in Austria

GI Dynamics, Inc. today announced the launch of the EndoBarrier Gastrointestinal Liner in Austria, the establishment of the first two Centers of Excellence and the treatment of patients at each new Center.

21 Sep 2011

Positive data from InVivo's biomaterial scaffold implant preclinical study on acute SCI

InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that in a rodent contusion model of SCI the Company's proprietary biopolymer scaffold showed positive preliminary data that indicate a therapeutic effect.

21 Sep 2011

MRI screenings for breast cancer benefit high-risk, underserved women

Using breast magnetic resonance imaging (MRI) screenings among targeted, high-risk, underserved women significantly decreased diagnostic cost and increased patient compliance rates with follow-up compared to using general risk mammography screenings.

21 Sep 2011

FDA clears Toshiba's advanced M-Power interface

Increasing MR exam efficiency, Toshiba America Medical Systems, Inc.'s advanced M-Power interface has received FDA clearance. M-Power is a customizable MR system user interface enabling technologists to streamline and accelerate scanning processes and enhance diagnoses.

21 Sep 2011